Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > If Grail's worth $8B, the superior ARISTOTLE is worth...???
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(94)
•••
Comment by gojotv!on Jun 08, 2021 12:36pm
78 Views
Post# 33348219

RE:If Grail's worth $8B, the superior ARISTOTLE is worth...???

RE:If Grail's worth $8B, the superior ARISTOTLE is worth...???Also, seeing the WAY Grail is being brought to market, through clinical networks, reveals that Tripp's plan was the only feasible one after all...
And our newly-acquired telehealth clinics, combined with drive-in and at at-home Covid testing for travel, shows StageZero to have a winning, multi-channel approach to marketing our tests, just as demand is poised to surge!
2021 is going to be memorable!
GLTA longs!


gojotv! wrote: How soon will investors figure out that StageZero is deployed, poised, and taking on the multi-cancer diagnostic blood test market?
June's a slow month, but success goes to the swift.
A  gleeful GLTA smart SZLS investors!


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities